IDEXX LABORATORIES INC /DE
For the period ended Sep 30, 2025. Filed Nov 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 3, 2025
IDXX$696.64-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $208,166 | $288,266 |
| Accounts receivable, net | 566,881 | 473,575 |
| Inventories | 391,564 | 381,877 |
| Other current assets | 310,444 | 256,179 |
| Total current assets | 1,477,055 | 1,399,897 |
| Long-Term Assets: | ||
| Property and equipment, net | 739,437 | 713,123 |
| Operating lease right-of-use assets | 128,207 | 116,129 |
| Goodwill | 413,651 | 405,100 |
| Intangible assets, net | 114,790 | 111,676 |
| Other long-term assets | 513,572 | 547,518 |
| Total long-term assets | 1,909,657 | 1,893,546 |
| TOTAL ASSETS | $3,386,712 | $3,293,443 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $122,265 | $114,211 |
| Accrued liabilities | 488,856 | 502,119 |
| Credit facility | 455,000 | 250,000 |
| Current portion of long-term debt | 149,997 | 167,787 |
| Current portion of deferred revenue | 35,693 | 33,799 |
| Total current liabilities | 1,251,811 | 1,067,916 |
| Long-Term Liabilities: | ||
| Deferred income tax liabilities | 3,724 | 11,312 |
| Long-term debt, net of current portion | 374,825 | 449,786 |
| Deferred revenue, net of current portion | 31,051 | 26,939 |
| Operating lease liabilities, net of current portion | 106,494 | 97,836 |
| Other long-term liabilities | 57,621 | 44,341 |
| Total long-term liabilities | 573,715 | 630,214 |
| Total liabilities | 1,825,526 | 1,698,130 |
| Commitments, Contingencies and Guarantees (Note 16) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 108,301 shares in 2025 and 107,836 shares in 2024; Outstanding: 79,999 shares in 2025 and 81,604 shares in 2024 | 10,830 | 10,784 |
| Additional paid-in capital | 1,792,787 | 1,673,863 |
| Deferred stock units: Outstanding: 60 units in 2025 and 60 units in 2024 | 6,229 | 5,885 |
| Retained earnings | 6,143,714 | 5,332,438 |
| Accumulated other comprehensive loss | (72,950) | (93,645) |
| Treasury stock, at cost: 28,303 shares in 2025 and 26,232 shares in 2024 | (6,319,424) | (5,334,012) |
| Total stockholders’ equity | 1,561,186 | 1,595,313 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $3,386,712 | $3,293,443 |
| The accompanying notes are an integral part of these condensed consolidated financial statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.